For younger and fit patients with r/r AML, current directions are focused on investigating the combinations of FLAG-Ida with 7–14 days of venetoclax demonstrating impressive results in the frontline setting, even for secondary AML [34,35]. This evidence concerns the gene IDUA and acute myeloid leukemia.